Table 2.
Summary of pharmacokinetic parameters from the base pharmacokinetic model
| Parameter | Point estimate | Standard error | % RSE |
|---|---|---|---|
| CL1, L/h | 24.7 | 3.71 | 15.0 |
| CL2, L/h | 3.76 | 0.601 | 16.0 |
| Vd, L | 6.51 | 0.357 | 5.48 |
| Variance (CL1) | 1.34 (CV = 116%) | 0.228 | 17.0% |
| Variance (CL2) | 1.19 (CV = 109%) | 0.189 | 15.9% |
| Variance (Vd) | 0.140 (CV = 37.4%) | 0.0207 | 14.8% |
| Covariance (CL1 and CL2) | 0.910 (R = .721) | 0.202 | 22.2% |
| Covariance (CL1 and Vd) | 0.294 (R = .679) | 0.0652 | 22.2% |
| Covariance (CL2 and Vd) | 0.355 (R = .870) | 0.0566 | 15.9% |
| Additive error (MEDI assay), ng/mL | 20.5 | 0.461 | 2.25% |
| Additive error (NCI assay), ng/mL | 8.95 | 0.359 | 4.01% |
| Proportional error | 0.414 | 0.00297 | 0.717% |
% RSE, percent relative standard error (100% × SE/EST); CL1, clearance for first dose (cycle 1, day 1); CL2, clearance for all subsequent doses; CV, coefficient of variation; MEDI, MedImmune; NCI, National Cancer Institute; R, correlation coefficient; SD, standard deviation; Vd, volume of distribution.